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Angiostatic treatment prior to chemo- or
photodynamic therapy improves
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Tumor vasculature is known to be poorly organized leading to increased leakage of molecules to the
extravascular space. This process can potentially increase interstitial fluid pressure impairing intra-tumoral
blood flow and oxygen supply, and can affect drug uptake. Anti-angiogenic therapies are believed to reduce
vascular permeability, potentially reducing interstitial fluid pressure and improving the extravasation of
small molecule-based chemotherapeutics. Here we show that pretreatment of human ovarian carcinoma
tumors with sub-optimal doses of the VEGFR targeting tyrosine kinase inhibitor axitinib, but not the EGFR
targeting kinase inhibitor erlotinib, induces a transient period of increased tumor oxygenation.
Doxorubicin administered within this window was found to enter the extravascular tumor space more
rapidly compared to doxorubicin when applied alone or outside this time window. Treatment with the
chemotherapeutics, doxorubicin and RAPTA-C, as well as applying photodynamic therapy during this
period of elevated oxygenation led to enhanced tumor growth inhibition. Improvement of therapy was not
observed when applied outside the window of increased oxygenation. Taken together, these findings further
confirm the hypothesis of angiostasis-induced vascular normalization and also help to understand the
interactions between anti-angiogenesis and other anti-cancer strategies.
A
fter reaching a critical size, the growth of a tumor becomes dependent on its ability to secure a blood supply
through the development of a vascular network1. This process is mediated by the release of angiogenic
growth factors by tumor cells in response to a hypoxic tumor microenvironment, initiating the growth of
new blood vessels, i.e. angiogenesis1–3. The presence of excessive pro-angiogenic growth factors, however, results in
a phenotypically aberrant tumor vasculature characterized by dilatation, tortuosity and increased permeability.
Such leakiness leads to protein extravasation and blood clotting, which impairs blood flow and induces high
interstitial fluid pressure (IFP) in the tumor4,5. Combined, these features contribute to poor perfusion in tumors
and consequently decreased uptake of chemotherapeutics6. In addition, they can result in reduced treatment
benefits of oxygen-dependent therapies such as radiotherapy7 and photodynamic therapy8. Moreover, many
anticancer drugs are less effective in hypoxic environments, which can exacerbate drug resistance9.
Several approaches have been developed to enhance intra-tumoral drug delivery, e.g. low-dose PDT10, the
application of a type I collagenase inhibitor11 and the use of various anti-angiogenic agents12–14. These treatments
result in a transient period where the morphology of the tumor vasculature appears more normal enabling
improved drug delivery. Moreover, it is well documented that appropriately tailored combined therapies show
synergism or additive anti-cancer effects15–18. Anti-angiogenic drug therapy is of particular interest as it can
counteract the upregulation of pro-angiogenic factors characteristic of the tumor microenvironment and, as a
form of anticancer therapy, ultimately aims to starve tumor growth through the inhibition of blood vessel
growth3. It has been shown that anti-VEGF, anti-VEGFR, or non-VEGF(R) targeting angiostatic compounds
can temporarily reduce the diameter of enlarged vessels and vessel tortuosity in time and dose dependent
manners, and can normalize the basement membrane19,20. Moreover, angiostatic therapy has been shown to
reduce vessel pore size leading to reduced interstitial fluid pressure and restore convective drug penetration,
facilitating the delivery and uptake of small molecules (below 12 nm in diameter), while simultaneously hinder-
ing the delivery of larger species6,12,21. As a consequence, intra-tumoral blood flow may increase giving rise to
enhanced tumor oxygenation. This anti-angiogenesis induced transient window of tumor blood vasculature
normalization has been exploited to apply other chemotherapeutics, at the appropriate time and dose, leading
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to improved treatment outcomes22,23. It should be noted, however,
that there is controversy over the existence of an angiostasis-induced
normalization window, and some groups have reported on absence
of increased drug delivery following angiostatic drug treatment24.
In the present study, we determined the window during which a
transient increase of intra-tumoral oxygenation, referred to as the
normalization window, takes place following treatment with targeted
angiostatic tyrosine kinase inhibitors (TKIs) in A2780 human
ovarian carcinoma xenografts implanted on the chicken chorioallan-
toicmembrane (CAM)model. Transient oxygenation enhancements
in the tumor were obtained after intravenous administration of the
VEGFR targeting small molecule TKIs axitinib (InlytaH) and suniti-
nib (SutentH), but not following treatment with the EGFR targeting
inhibitor erlotinib (TarcevaH). We subsequently used the axitinib-
induced normalization window for combination therapy with PDT,
as well as with two small molecule-based chemotherapeutics, i.e.
doxorubicin (8 nm in diameter) and [Ru(g6-p-cymene)Cl2(pta)],
where pta 5 1,3,5-triaza-7-phosphaadamantane (RAPTA-C; 1 nm
in diameter), a ruthenium-based anti-cancer and anti-metastatic
drug under development25–27. In all the combination therapies eval-
uated, improved anti-tumor efficacy was observed when the treat-
ment was performed during the axitinib-induced normalization
window, compared to tumors treated with the same compounds
without an axitinib pretreatment or when applied outside the nor-
malization window.
Results
Axitinibandsunitinibat suboptimaldoses induce transiently increased
tumoroxygenation.Oxygenation of human A2780 ovarian carcinoma
tumors, that are negative for EGFR, xenografted onto the chorioalla-
ntoic membrane of chicken embryos was studied following treatment
with the anti-angiogenic tyrosine kinase inhibitors (TKIs) axitinib,
sunitinib or erlotinib (Fig. 1A). Each drug was given i.v. at time t 5
0 and followed by a second i.v. injection at 24 hours. Oxygen partial
pressure (pO2) was measured in tumors at various time points after
the first i.v. drug administration by inserting the pO2 probe into the
tumor core. The TKIs were administered at the following doses:
axitinib at 4.5 mg/kg (Fig. 1B) and 36 mg/kg (Fig. 1C), sunitinib at
70 mg/kg (Fig. 1D), and erlotinib at 50 mg/kg (Fig. 1E). The pO2
measurements in control tumors were performed at the same time
points. Overall tumor growth was monitored over 7 days after the first
TKI injection (Supplementary Fig. S1). At the applied drug doses,
inhibition of A2780 tumor growth was sub-optimal, i.e. by appro-
ximately 7% (axitinib 4.5 mg/kg; p 5 0.70; n 5 26) and 40%
(axitinib 36 mg/kg; p 5 0.07; n 5 15), 25% (sunitinib; p 5 0.04; n
5 7), and by approximately 28% (data for erlotinib 40 and 80 mg/kg; p
5 0.32 and 0.02; n 5 12 and 13, respectively).
Axitinib administered at low dose of 4.5 mg/kg (Fig. 1B) did not
induce a significant increase in intratumoral pO2, measured between
24 and 54 hours after the first injection of axitinib. At a higher dose of
axitinib (36 mg/kg), a significant increase in tumor oxygenation of
31% was observed, with a maximum identified at 30 hours after the
first drug injection (Fig. 1C; **p, 0.01 at t 5 27 h and t 5 30 h; *p
, 0.05 at t 5 48 h). Sunitinib also induced a significant increase in
tumor oxygenation between 24 and 48 hours after administration of
the first drug leading to amaximal oxygenation increase of 47% at t5
27 h (Fig. 1C; *p, 0.05). Axitinib showed a more stable normaliza-
tion window compared to sunitinib, with clear start and end points.
Consequently, axitinib was used for the subsequent combination
studies.
The axitinib-induced vascular normalization window increases
doxorubicin extravasation. To investigate whether the identified
Figure 1 | Oxygen partial pressure (pO2) measured in tumors treated with axitinib, sunitinib and erlotinib. (A). Time schedule of pO2 measurements
(shown in red) after two intravenous injections of (B) axitinib (4.5 mg/kg, n5 2–11), (C) axitinib (36 mg/kg, n5 6–12; **p 5 0.004 and 0.003, *p 5 0.03
for 27 h, 30 h and 48 h, respectively), (D) sunitinib (70 mg/kg, n5 9–15; *p, 0.04 (27 h), **p5 1.7E2 7 (30 h), **p5 3.5E2 4 (48 h), and *p5 0.015
(51 h), or (E) erlotinib (n 5 5–10). Values are normalized to the pO2 values measured in untreated tumors (% control).
www.nature.com/scientificreports
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normalization window could be exploited to increase drug delivery,
doxorubicin (abbreviated to ‘DOX’) at 15 mg/kg was administered
i.v. in a 100 ml bolus, within the normalization window (i.e. 30 hours
post initial axitinib administration; referred to as ‘in NW’) and before
the normalization window (at 24 hours post initial axitinib
administration; referred to as ‘out NW’). A control group received
only DOX and was included to establish the distribution of DOX in
non-pre-treated tumors. The ratio of DOX present in the tumor
tissue versus the CAM vasculature was quantified using the
intrinsic fluorescence of DOX (excited at lex 5 470 6 20 nm; lem
$ 520 nm), as previously reported28. Fluorescence images were
acquired for each treatment group 1, 2, 5, 8 and 15 minutes post
DOX injection (images of the ‘CTRL-DOX’ group are provided in
Fig. 2A, and red arrows indicate tumor blood vessels where the
gradual extravasation of DOX becomes visible with time). An
accelerated leakage of DOX from the tumor vasculature into the
tumor parenchyma was observed when DOX was administered
within the axitinib-induced normalization window (at 30 hours after
the initial administration of axitinib). In contrast to the ‘CTRL-DOX’
and ‘out NW’ groups, extravasation of DOX was observed even after 1
minute in the ‘in NW’ group. Despite the fact that DOX, once taken
up into the tumor cells binds to DNA and loses its fluorescence,
quantification of the fluorescence images indicates an increase in the
rate of DOX leakage in the ‘in NW’ group relative to the other groups.
At the final time point of 15 minutes there is ca. 2.5-fold higher
fluorescence in the tumor tissue than in the blood vessels in the ‘in
NW’ group, compared to an increase of only 1.5-fold in the ‘CTRL-
DOX’ group, see Figure 2B. Interestingly, the ‘out NW’ group shows a
lower ratio of fluorescence between the tumor and blood vessels,
indicating that this treatment possibly reduces the leakage of DOX
from the vessels into the tumor tissue, with an almost equivalent
fluorescence at 15 min. The enhanced ratio in the ‘in NW’ group is
an underestimation of enhanced extravasation because of the above-
mentioned DNA binding. Administration of DOX ‘out NW’ did not
increase the extravasation (p 5 0.53 vs. CTRL).
Tumor growth inhibition of doxorubicin and RAPTA-C in the
axitinib-induced vascular normalization window. To test whether
the increased drug delivery results in enhanced anti-tumor efficacy
tumor growth experiments were performed. Tumors were trans-
planted onto the CAM and treatment was initiated on embryo
development day (EDD) 11 in order to monitor tumor growth over
a period of 7 days. The doxorubicin dose was reduced to 3 mg/kg,
which is suboptimal to avoid lethality to the embryos. Tumor growth
curves confirmed that anti-tumor efficacy of doxorubicin is strongly
enhanced when administered in the normalization window (‘in NW’)
(Fig. 3A). Doxorubicin alone did not inhibit tumor growth and
axitinib alone reduced growth by approximately 40% (p , 0.07 as
compared to control). The combination therapy of giving DOX in the
normalization window significantly improved efficacy and inhibited
tumor growth by 78% (**p , 0.0001 vs. DOX; **p 5 0.005 vs ‘out
NW’). Interestingly, application of DOX outside the normalization
window (‘out NW’) did not improve the efficacy of the combination
(Fig. 3A). These results are in accordance with the extravasation of
DOX to the tumor tissue (Fig. 2B). Immunohistochemical staining
with the CD31 antibody showed that the suboptimal doses of drugs
did not significantly change the microvessel density (MVD) in this
experiment.
Enhanced tumor growth inhibition was also demonstrated for the
experimental ruthenium-based compound RAPTA-C. RAPTA-C
treatment at 400 mg/kg did not affect tumor growth when adminis-
tered alone (Fig. 4A; n 5 7, p 5 0.38). When applied in combination
with axitinib (‘in NW’), this ineffective dose of RAPTA-C signifi-
cantly inhibited tumor growth by 83.5% compared to the control
group (n 5 6; **p 5 0.0015; **p 5 0.0005 vs. ‘out NW’). This
treatment was also more effective than the ‘out NW’ treatment,
Figure 2 | Effect of vascular normalization using axitinib on the uptake of DOX into the tumor tissue. (A). Representative fluorescence images of
tumors after the administration of DOX (15 mg/kg). Red arrows highlight a representative tumor vessel where the extravasation of DOX is visible.
(B). Quantification of DOX distribution as a function of time without an axitinib pre-treatment (‘CTRL-DOX’), with DOX administered in the axitinib-
induced normalization window at t 5 30 h (‘in NW’) and with DOX administered before the axitinib-induced normalization window t 5 24 h (‘out
NW’). Images were taken at 4x magnification. White bar in the upper right corner represents 0.5 cm and is valid for all images. *p, 0.042 between ‘in
NW’ and ‘out NW’; n 5 3–10.
www.nature.com/scientificreports
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which inhibited tumor growth by approximately 60% (n 5 7, p 5
0.08 vs. CTRL). Microvessel density assessment showed that the ‘in
NW’ group had a slight but significantly reduced MVD as compared
to control tumor (*p, 0.048, n 5 15–18). RAPTA-C itself showed a
slight but significant increase inMVD, which was not changed by the
application of axitinib outside the normalization window (*p 5
0.011 and **p 5 0.003, n 5 11 and n 5 19 for ‘RAPTA-C’ and
‘out NW’ groups, respectively).
In order to understand the improved anti-tumor efficacy seen
when combining axitinib with DOX or RAPTA-C in vivo, these
compounds were tested separately or in combination in vitro on
immortalized human endothelial (ECRF24) cells and human ovarian
carcinoma (A2780) cells. As shown in Supplementary Table S1, two
doses of each compound were identified to inhibit cell proliferation
by 40% or less, mimicking in vivo conditions. The combinatory index
(CI) was calculated for each pair of compounds in each cell line based
on in vitro single drug and combination efficacies and was used as an
indicator of synergy (CI, 0.8). These results showed that, under the
conditions tested, axitinib in combination with doxorubicin did not
result in a synergistic inhibition of cell proliferation in either of the
cell lines (CI. 0.8), while the combination of axitinib with RAPTA-
C led to a synergistic interaction in the ECRF24 cells but only an
additive (CI 5 1) or even slight antagonistic (CI 5 1.3) effect in
A2780 cells.
Effect of low-dose PDT on tumor growth following pretreatment
with axitinib. To investigate whether the axitinib-induced norma-
lization window could potentiate tumor oxygenation dependent
Figure 3 | Enhanced effect of DOX after pretreatment with axitinib. (A). Tumor growth curves of the different treatment groups (n 5 6–13). Axitinib
(36 mg/kg) was administered on days 1 and 2 andDOX (3 mg/kg) was administered on day 2 at 24 h for ‘out NW’, 27 h for DOX and 30 h for ‘in NW’ (n
5 6–24). Tumor size wasmonitored daily for 7 consecutive days (axitinib 36 mg/kg: n5 15, p5 0.07; ‘DOX 3 mg/kg’: n5 10, p5 0.30; ‘inNW’ vs. CTRL
n5 9, **p5 0.005; ‘out NW’ vs. CTRL: n5 7, p5 0.28, 2-way ANOVA). (B). Representative images of tumors resected on the last experimental day from
each group stained for CD31. Images were taken at 100x magnification, the bar in the top left image representing 20 mm. (C). Quantification of the
microvessels (n 5 3–24). Error bars in (A) and (C) represent standard error of mean, significance indicated vs CTRL, and *p , 0.05 and **p , .01.
Figure 4 | Enhanced effect of RAPTA-C on tumor growth after prior treatment with axitinib. (A). Tumor growth curves. Administration of axitinib on
day 1 and 2 and RAPTA-C on day 2 (n 5 6; **p 5 0.0015 for ‘in NW’ vs. CTRL; p 5 0.08 for ‘out NW’ vs. CTRL, and p 5 0.07 for axitinib, 2-way
ANOVA). (B). Representative CD31 staining images. Images were taken at 200x magnification; the bar in the top left image represents 10 mm.
(C). Quantification ofmicrovessel density (represented as a percentage of the control, n5 4–18). Error bars in (A) and (C) represent standard error of the
mean, significance is indicated vs. CTRL, and *p , 0.05 and **p , 0.01.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8990 | DOI: 10.1038/srep08990 4
therapies, the effect of PDT was evaluated (Fig. 5). In order to define
PDT conditions leading to suboptimal tumor growth inhibition,
A2780 tumors were first treated with VisudyneH-PDT (0.2 mg/kg
embryo weight; lex 5 420 6 20 nm, drug-light interval 1 min) at
various low light fluencies (1, 2.5 or 5 J/cm2, irradiance 28.5 6
1.7 mW/cm2). At 2.5 J/cm2 tumor growth was inhibited non-
significantly by 30% (Supplementary Fig. S2).
While VisudyneH-PDT and axitinib (36 mg/kg) inhibited tumor
growth by 30% (*p 5 0.014) and 40% (p , 0.07), respectively, a
reduction of tumor growth by 66% (n5 15, **p, 0.0001, compared
to the axitinib group) was observed when treating tumors with
VisudyneH-PDT at 30 hours after the first injection of axitinib (‘in
NW’; Fig. 5A). Application of PDT out of the normalization window
(‘out NW’) did not show enhanced effects compared to axitinib
alone. Immunohistochemical staining with the CD31 antibody
(Figure 5B) showed that the VisudyneH-PDT applied ‘in NW’
resulted in decrease of the microvessel density (MVD), see Fig. 5C.
VisudyneH-PDT was also combined with a lower axitinib dose
(4.5 mg/kg, where no significant increase in tumor oxygenation
was measured (Fig. 1B) applied at the same treatment schedules
(Supplementary Fig S2B). Performing PDT at 30 hours after the first
axitinib administration (‘in NW’) slightly enhanced the treatment
efficacy (41% tumor growth inhibition; p 5 0.11 vs. CTRL, n 5 7)
compared to the ‘out NW’ group (23% tumor growth inhibition; p 5
0.788 vs. ‘in NW’, n 5 15). The overall axitinib dose in the ‘in NW’
group was then increased to 13.5 mg/kg by administering axitinib for
the third time 24 hours after PDT. This improved the treatment
efficacy by 23% compared to the ‘in NW’ group (Supplementary
Fig S3; ‘in NW 3 injections’; 64% tumor growth inhibition; n 5 8).
The tumor growth inhibition of the ‘in NW 3 injections’ group was
comparable with the anti-tumor effect of PDT applied in the nor-
malization window induced by axitinib at 36 mg/kg (total dose of
72 mg/kg). Interestingly, shifting the first axitinib injection in the
‘out NW’ group to 4 hours after PDT (Supplementary Fig. S3; ‘out
NW (4 h)’; 25% tumor growth inhibition; p 5 0.62, n 5 10) resulted
in similar tumor growth inhibition in comparison to injecting the
drug right after PDT (‘out NW’). These treatments did not provide
better overall anti-cancer effect than the one observed with using
normalization window. These results along with the intra-tumoral
oxygenation measurements (Fig. 1) suggest that the timing between
the axitinib administration and the PDT treatment, as well as the
dose of the anti-angiogenic drug administered are both crucial for
optimally exploiting the normalization window.
Discussion
The effect of a pretreatment step was studied with the tyrosine kinase
inhibitor (TKI), axitinib, on intra-tumoral delivery of small mole-
cule-based chemotherapeutics on human ovarian carcinoma
(A2780) xenografted on the chicken chorioallantoic membrane
(CAM) model. Exposure to axitinib and sunitinib results in a period
of enhanced oxygenation of the tumor. Axitinib induces a normal-
ization window that leads to enhanced drug delivery as well as to
improved efficacy of these drugs. Moreover, axitinib pretreatment
potentiates the efficacy of vaso-occlusive VisudyneH-photodynamic
therapy, a treatmentmodality that depends on sufficient oxygenation
of the tumor tissue.
A variety of pre-clinical and clinical evidence is available that both
supports and refutes the existence of a normalization window
induced by angiostatic therapy. Various groups have reported mea-
surable increases in tumor oxygenation, improved drug delivery, and
effects on vessel function and morphology (permeability and/or
blood flow), as indicators of vascular normalization after treatment
with various angiostatic agents29. Increased oxygenation has been
reported following the administration of bevacizumab13,30, tyrosine
kinase inhibitors, e.g. sunitinib31, semaxanib32, a PI3K inhibitor33,
EGFR inhibitors33,34, the cox-2 inhibitor apricoxib35, as well as fol-
lowing other angiostatic therapies, such as metronomic chemother-
apy36. Enhanced delivery of doxorubicin has also been shown
following the overexpression of platelet-derived growth factor-D
(PDGF-D) in breast carcinoma37. Clinical evidence that supports
vascular normalization includes reduced permeability and reduced
tumor-associated edema38,39 following treatment with the pan-
VEGFR inhibiting TKI cediranib in patients with recurrent gliblas-
toma, as well as reduced interstitial fluid pressure and improved
delivery of fluorodeoxyglucose following bevacizumab treatment in
rectal carcinoma40.
On the other hand, there are studies suggesting that the improved
efficacy of angiogenesis inhibitors with other chemotherapeutics,
does not involve enhanced oxygenation or drug delivery, and some
even indicate that combinations are sometimes not beneficial24,41–43.
Figure 5 | Effect of low-dose PDT on tumor growth following vascular normalization with axitinib. Normalized A2780 tumor volume (% control)
monitored between treatment day 1 to 7. (A). Tumors were treated with VisudyneH-PDT (2.5 J/cm2; n 5 36), axitinib (36 mg/kg; n 5 15), or the
combination of both performed within (‘in NW’ vs. CTRL; **p 5 0.0001, n 5 15) or before (‘out NW’ vs. CTRL; *p 5 0.04, n 5 8, 2-way ANOVA) tumor
oxygenation enhancement. (B). Representative images of tumor from each group stained for CD31 in tumors resected on the last experimental day. Images
were taken at 200xmagnification, the bar in the top right image represents 10 mm. (C). Quantification of theMVD represented as a percentage of the control
(n 5 3–18). Error bars in (A) and (C) correspond to the standard error of mean, significance indicated vs CTRL, and *p , 0.05 and **p , 0.01.
www.nature.com/scientificreports
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In a clinical setting, Van der Veldt et al. reported reduced perfusion
and a reduced net influx rate of docetaxel in patients with non-
small cell lung cancer (NSCLC) following bevacizumab therapy
(15 mg/kg), noticeable at 5 hours and lasting for 4 days24. In a pre-
clinical study where axitinib was administered (10, 25 or 50 mg/kg
once daily by oral gavage) 1 hour before or 1 hour after radiotherapy
in mice implanted with human prostate tumors, it was shown that
after the combination therapy the tumor vasculature was not func-
tionally normalized and an increase in intra-tumor hypoxia was
observed41,42. In another study axitinib (25 mg/kg injected intraper-
itoneally once daily) induced tumor hypoxia and seemed to suppress
tumor blood perfusion, thereby decreasing the uptake of the tested
chemotherapeutic drug in mice xenografted with rat gliosarcoma
cells43. However, in these studies an axitinib induced normalization
windowwas not clearly identified, and direct measurements of intra-
tumor oxygen levels after axitinib treatment were not performed.
More recently, the effect of low-dose axitinib (2–25 mg/kg admini-
strated orally twice daily) was evaluated in combination with cyclo-
phosphamide and a significantly increase in tumor retention of the
chemotherapeutic drug was observed, indicating that the dosage and
timing of drug administration is critical in identifying a normaliza-
tion effect44.
While it is clear that there is still debate about the existence, the
nature and the benefits of angiostasis-induced vascular normaliza-
tion, in our studies the measured intratumoral oxygen partial pres-
sure (pO2) was used as an indicator of tumor normalization. It was
assumed that an increase in the pO2 is linked to a decrease in the
interstitial fluid pressure and temporal vascular modulation, i.e. nor-
malization. As previously described, such a normalization reduces
the pore size on vasculature in solid tumors limiting vessel permeab-
ility for molecules larger than 12 nm in diameter, but enabling smal-
ler-sized molecules to enter tumor space more easily/rapidly12. We
subsequently found that administration of small molecule che-
motherapeutics, i.e. doxorubicin (8 nm in diameter) or RAPTA-C
(1 nm), during this normalization period led to a significant
enhancement of extravasation of these drugs and improved overall
tumor growth inhibition. Since RAPTA-C does not have an intrinsic
fluorescence it could not be detected in vivo and therefore was admi-
nistered at the same time schedule as DOX. Interestingly, RAPTA-C
administered at lower dose (0.4 mg/kg) than DOX (3 mg/kg) was a
more potent inhibitor of tumor growth. This finding is quite remark-
able as RAPTA-C has low toxicity and when used as a monotherapy
requires doses of 100 mg/kg injected daily over a number of days to
have a similar effect on tumor inhibition26. Based on histology and in
vitro experiments in ECRF24 endothelial cells it would appear that
RAPTA-C inhibits tumor growth via both vascular modulation/nor-
malization and anti-angiogenic25 mechanisms.
In our experimental regimen we were unable to induce a normal-
ization window following treatment with erlotinib, the EGFR inhib-
itor, at 50 mg/kg, a dose that inhibits tumor growth by approximately
28%. This effect is almost equivalent to the efficacy of the dose used
for sunitinib (inhibiting tumor growth by 25% vs. CTRL). It is con-
ceivable that an increase in tumor oxygenation could appear beyond
the time frame used in the study. The identification of a normaliza-
tion window following erlotinib administration in mice bearing
xenografts of head and neck squamous cell carcinoma (SQ20B) cells
has been reported34. A possible explanation for these differing obser-
vations may be due to the sensitivity of tumor types to EGFR inhibi-
tion, as head and neck tumors frequently overexpress EGFR45 and the
A2780 ovarian carcinoma cell line used for xenografted tumors in
this study are EGFR negative46.
Our study indicates that tumor vessel normalization induced by
axitinib is time and dose dependent. As axitinib has a restricted
targeting spectrum and higher affinity for VEGF receptors than
sunitinib, it may be argued that the induced vessel normalization
effect seems to be VEGFR-related. The fact that we did not see
enhanced oxygenation by the EGF targeted TKI erlotinib, further
supports this suggestion. We have previously reported on the syn-
ergistic inhibition of tumor growth through the combination of sub-
optimal doses anti-angiogenic TKIs with low-dose PDT47, showing
that enhanced tumor growth inhibitionmay be achieved through the
inhibition of PDT-induced angiogenic tissue responses, without the
induction of vascular normalization. In this study we further inves-
tigated the intra-therapy time-dependent design of such a combina-
tion. PDT is a highly oxygen dependent therapy8, and its application
during enhanced oxygenation period was found to improve the its
anti-tumor effect. The delayed benefit in the PDT-related experi-
ments may be due to the fact that PDT has been shown to induce
angiogenesis that may counteract the effect of the angiogenesis
inhibitor.
To date, the clinical efficacy in cancer patients of cytotoxic drugs
combined with angiogenesis inhibitors is limited. As shown in a
phase III trial, the treatment of newly diagnosed glioblastoma
patients treated with bevacizumab prior temozolomide therapy did
not improve the survival outcome48. Reduced perfusion and a
reduced net influx rate of docetaxel in patients with NSCLC follow-
ing bevacizumab therapy (15 mg/kg) was reported24. The feasibility
of clinical applications of the normalization phenomenon (e.g. in a
situation where the normalization window is induced for approxi-
mately 6 days30 and hyperfractionated radiotherapy is administered 5
times per week49) is widely discussed. It has been argued that in
certain conditions there may even be a lack of real clinical benefit
from vascular normalization, e.g. for the use of anti-VEGF antibody
therapy in the case of cerebral tumors where normalization may
reduce drug delivery by helping the re-establishment of brain micro-
vasculature which is normally characterized by reduced permeab-
ility50. However, our studies confirm that vascular normalization and
treatment benefit can be obtained with VEGFR-targeting small
molecule-based inhibitors. Normalization can both enhance extra-
vasation of small molecule chemotherapeutics to the intratumoral
space, as well as enhance oxygen dependent treatment strategies. Our
study also stresses the need for precise timing and scheduling of the
combination treatment51. Further development of the encouraging
results reported here in more advanced preclinical models will
require extensive efforts to identify optimized dosages and timing
schedules to maximally exploit the potential therapeutic benefits of
such treatment strategies.
Methods
Cells lines and reagents. A2780 human ovarian carcinoma cells (ECACC, Salisbury,
UK) were maintained in RPMI-1640 cell culture medium supplemented with
GlutaMAXTM (Gibco, Carlsbad, USA), 10% heat-inactivated bovine calf serum
(Sigma-Aldrich, St. Louis, USA) and 1% antibiotics (Sigma-Aldrich). Immortalized
human vascular endothelial cells (ECRF24) were maintained in medium containing
50% DMEM and 50% RPMI 1640 supplemented with 1% of antibiotics (Life
Technologies, Carlsbad, California, USA). ECRF24 were always cultured on 0.2%
gelatin coated surfaces.
RAPTA-C ([Ru(g6-p-cymene)Cl2(pta)] (pta is 1,3,5-triaza-7-phosphaadaman-
tane)) was synthesized and purified as described previously52. RAPTA-C was freshly
prepared prior to use by dissolving power in DMSO at a concentration of 150 mg/ml.
Axitinib was purchased from LC laboratories (Woburn, MA, USA) and dissolved in
DMSO at a concentration of 20 mM at stored at 220uC for subsequent use.
Doxorubicin HCl was acquired from Pharmachemie BV, Haarlem, The Netherlands,
and was freshly dissolved in DMSO at 10 mg/ml. Drug dilutions were prepared in
0.9%NaCl solution for in vivoCAMassays or the appropriate cell medium for in vitro
assays.
In ovo pO2 measurements. Oxygen partial pressure (pO2) within tumors was
recorded with an OxyLab pO2 meter (Oxford Optronix Ltd., Oxford, UK) coupled to
a calibrated fiber optic probe (NP/O/E) placed in a 23 G surgical steel needle. The
measurements were recorded 60 seconds after the insertion of the needle into the
tumor core. pO2 measured in untreated tumors were compared to the measurements
obtained in tumors treated with axitinib (4.5 or 36 mg/kg of axitinib), sunitinib
(70 mg/kg) or erlotinib (50 mg/kg) injected on EDD 13 (t 5 0) and followed by a
second injection of the same drug dose on EDD 14 (t 5 24 h).
Fluorescence quantification. The CAM vasculature was visualised with a Nikon
Eclipse E600FN epi-fluorescence microscope (Nikon AG, Tokyo, Japan) and a Plan
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Fluor objective 10 3 0.3 (working distance: 16 mm, Nikon AG). Intravenous
injection of doxorubicin (1.5 mg/mL) induced the blood vessels fluorescence that
enabled angiography. Contrast was improved with 100 ml injection of India ink into
the extra-embryonic space (Pelikan, Witzikon, Switzerland). Fluorescence
angiographies were taken every 30 seconds for 15 minutes. Fluorescence
angiographies were analysed with ImageJ software (version 1.40 a; National Institutes
of Health, Bethesda, MD, USA). The fluorescence quantification of doxorubicin
distribution was performed by evaluating the average pixels value in the specified
regions. To do that, three areas were established (within a blood vessel, within the
tumour tissue and a peripheral background area) and the average pixel value in each
of these regions was recorded at each of the desired time points. This data was then
presented as the ratio of the average pixel value in the tumor tissue as compared to in
the blood vessel, with both value corrected for the background by subtracting the
average background fluorescence.
Tumor growth inhibition. Fertilized chicken eggs were incubated in a hatching
incubator (relative humidity 65%, 37uC), as previously described53. A2780 cells (106)
were prepared in serum-free RPMI-1640 as a spheroid in a 25 ml hanging drop and
3 h later were transplanted on the surface of the in ovo CAM on EDD 854.
Vascularized three-dimensional tumors were visible 3 days after tumor cell
implantation, on EDD 11, when treatment was initiated. Tumors were treated daily
by i.v. injection of freshly prepared compounds into a main blood vessel of the CAM,
i.e. (i) axitinib, (ii) RAPTA-C (iii) doxorubicin and combinations of (i) and (ii), or (i)
and (iii). Tumors weremonitored daily andmeasured (volume5 [larger diameter]3
[perpendicular diameter]2 3 0.52). At the last experiment day embryos were
sacrificed and tumors were resected and fixed in zinc-fixative for additional analysis.
Low light fluence VisudyneH-PDT (1 J/cm2, 2.5 J/cm2, 5 J/cm2) was performed on
EDD 11 (lex 5 420 nm, lem . 470 nm, irradiance of 28.5 6 1.72 mW/cm2), as a
single therapy, or at a dose of 2.5 J/cm2 in combination with axitinib (4.5 or 36 mg/kg)
at t 5 24 or 30 h after the initial axitinib injection on EDD11. When tumors were
treated with PDT, the size of the diaphragm was adjusted so that the area of
irradiation exactly corresponded to the visible tumor area.
Tumor samples and immunohistochemistry. On the last day of the experiment,
tumors were resected and fixed overnight in zinc fixative solution. CAM tumors were
stained as previously described26. Briefly, 5 mm sections were blocked with 5% BSA in
PBS followed by incubation with primary antibodies against CD31 (rat anti-CD31;
15200, clone SZ31, Dianova, Hamburg, Germany). Secondary donkey anti-rat
biotinylated antibodies (15200; Jackson, Suffolk, UK) were then incubated, followed
by Streptavidin-HRP (1550; Dako, Glostrup, Denmark), and visualized by 3,3’-
diaminobenzidine (DAB), resulting in a brown-colored precipitate at the antigen site.
In vitro study on synergy between axitinib and doxorubicin or axitinib and
RAPTA-C. Cell viability and migration assays were performed as previously
described25. Cells were seeded in a 96-well culture plate at a density of 10 3 103 cells/
well 24 hours prior to drug administration. After applying compounds at their desired
concentrations, cells were incubated with drugs for 72 h. Cell viability was assessed
using the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI,
USA).
Statistical analysis. Values are given as mean values 6 standard error of the mean
(SEM) after independent experiments performed several times. Statistical analyses
were done using the two-way ANOVA test for in vivo tumor growth studies or a two-
tailed student t-test for other data. P-values , 0.05 were considered as being
statistically significant.
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